Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Leerink Swann increased their Q3 2017 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst G. Porges now forecasts that the pharmaceutical company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.11. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Vertex Pharmaceuticals’ FY2017 earnings at $0.60 EPS and FY2018 earnings at $1.35 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million for the quarter, compared to analysts’ expectations of $489.95 million. During the same quarter in the previous year, the company earned $0.24 earnings per share. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Vertex Pharmaceuticals Incorporated Increased by Analyst (VRTX)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/19/q3-2017-eps-estimates-for-vertex-pharmaceuticals-incorporated-increased-by-analyst-vrtx.html.

Other analysts have also recently issued reports about the stock. Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Robert W. Baird restated an “outperform” rating and issued a $171.00 price target (up from $136.00) on shares of Vertex Pharmaceuticals in a report on Friday, July 21st. Royal Bank Of Canada raised their price target on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday. Cowen and Company restated a “market perform” rating and issued a $105.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, July 6th. Finally, UBS AG cut shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the company from $135.00 to $174.00 in a report on Wednesday, July 19th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus target price of $167.25.

Shares of Vertex Pharmaceuticals (VRTX) opened at 154.76 on Wednesday. Vertex Pharmaceuticals has a 52 week low of $71.46 and a 52 week high of $167.85. The company has a market cap of $39.02 billion, a price-to-earnings ratio of 148.66 and a beta of 1.73. The stock’s 50 day moving average is $154.36 and its 200-day moving average is $137.17.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sowell Financial Services LLC increased its holdings in Vertex Pharmaceuticals by 0.8% in the 1st quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock worth $325,000 after acquiring an additional 23 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after acquiring an additional 75 shares in the last quarter. Buckingham Asset Management LLC increased its holdings in Vertex Pharmaceuticals by 3.6% in the 2nd quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock worth $292,000 after acquiring an additional 79 shares in the last quarter. Eqis Capital Management Inc. increased its holdings in Vertex Pharmaceuticals by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 14,549 shares of the pharmaceutical company’s stock worth $1,875,000 after acquiring an additional 83 shares in the last quarter. Finally, Grandfield & Dodd LLC increased its holdings in Vertex Pharmaceuticals by 1.6% in the 2nd quarter. Grandfield & Dodd LLC now owns 5,805 shares of the pharmaceutical company’s stock worth $748,000 after acquiring an additional 90 shares in the last quarter. 92.82% of the stock is owned by institutional investors.

In related news, SVP Paul M. Silva sold 860 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $152.99, for a total value of $131,571.40. Following the completion of the sale, the senior vice president now owns 17,494 shares of the company’s stock, valued at approximately $2,676,407.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Paul M. Silva sold 43,443 shares of the business’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $161.07, for a total transaction of $6,997,364.01. Following the completion of the sale, the senior vice president now directly owns 26,516 shares of the company’s stock, valued at approximately $4,270,932.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 512,923 shares of company stock valued at $82,259,024. Insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.